BMC Musculoskeletal Disorders (Sep 2021)

Influence of IGF-I serum concentration on muscular regeneration capacity in patients with sarcopenia

  • Stefanie Jarmusch,
  • Lisa Baber,
  • Martin Bidlingmaier,
  • Uta Ferrari,
  • Fabian Hofmeister,
  • Stefan Hintze,
  • Stefan Mehaffey,
  • Peter Meinke,
  • Carl Neuerburg,
  • Benedikt Schoser,
  • Fabiana Tanganelli,
  • Michael Drey

DOI
https://doi.org/10.1186/s12891-021-04699-3
Journal volume & issue
Vol. 22, no. 1
pp. 1 – 11

Abstract

Read online

Abstract Background Previous research has described a neuroprotective effect of IGF-I, supporting neuronal survival, axon growth and proliferation of muscle cells. Therefore, the association between IGF-I concentration, muscle histology and electrophysiological markers in a cohort of patients with sarcopenia dares investigation. Methods Measurement of serum concentrations of IGF-I and binding partners, electromyographic measurements with the MUNIX (Motor Unit Number Index) method and muscle biopsies were performed in 31 patients with acute hip fracture older age 60 years. Molecular markers for denervation (neural cell adhesion molecule NCAM) and proliferation markers (Ki67) were assessed by immunofluorescence staining of muscle biopsy tissue. Skeletal muscle mass by bioelectrical impedance analysis and hand-grip strength were measured to assess sarcopenia status according to EWGSOP2 criteria. Results Thirty-one patients (20 women) with a mean age of 80.6 ± 7.4 years were included. Concentrations of IGF-I and its binding partners were significantly associated with sarcopenia (ß = − 0.360; p = 0.047) and MUNIX (ß = 0.512; p = 0.005). Further, expression of NCAM (ß = 0.380; p = 0.039) and Ki67 (ß = 0.424; p = 0.022) showed significant associations to IGF-I concentrations. Conclusions The findings suggest a pathogenetic role of IGF-I in sarcopenia based on muscle denervation.

Keywords